Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

FLEX PHARMA INC (FLKS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
4.11(c) 4.26(c) 4.36(c) 4.2799(c) 4.3(c) Last
11 986 133 210 109 147 45 659 23 106 Volume
-1.44% +3.65% +2.35% -1.84% +0.47% Change
More quotes
Financials ($)
Sales 2017 1,45 M
EBIT 2017 -36,9 M
Net income 2017 -36,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 3,15 M
EBIT 2018 -44,8 M
Net income 2018 -44,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 53,5x
Capi. / Sales2018 24,5x
Capitalization 77,3 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company.It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company operates through two segments: Consumer Operations and Drug Development.The... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
02/15FLEX PHARMA : Presenting at BIO CEO on February 13, 2018
AQ
02/08FLEX PHARMA : New Study Shows HOTSHOT™ Provides Relief From Muscle Sorenes..
PR
02/06FLEX PHARMA : Presenting at BIO CEO on February 13, 2018
BU
02/05FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Departure of Directors or Certain ..
AQ
02/05FLEX PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/22FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Regulation FD Disclosure
AQ
01/22FLEX PHARMA, INC. : Regulation FD Disclosure (form 8-K)
AQ
01/12FLEX PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2017FLEX PHARMA : Completes Patient Enrollment in Phase 2 Trial of Muscle-relaxing C..
AQ
2017FLEX PHARMA : Enrollment Completed in Flex Pharma's Phase 2 Exploratory Spastici..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
12:40pFlex Pharma $FLKS Lifted to Hold at Zacks Investment Research  
07:34aFlex Pharma Inc $FLKS Given Average Rating of “Buy” by Brokerages  
02/15Jefferies Group Lowers Flex Pharma FY2018 Earnings Estimates to ($1.68) EPS (.. 
02/14Jefferies Group Sets Flex Pharma FY2022 Earnings Estimates at ($0.08) EPS.  
02/13Flex Pharma $FLKS Given Coverage Optimism Rating of 0.02  
More tweets
Qtime:42
News from SeekingAlpha
02/09Key events next week - healthcare 
01/22Flex Pharma hires advisor to assist with strategic alternatives for HOTSHOT b.. 
01/08After Hours Gainers / Losers 
01/03More new coverage - healthcare 
2017Flex Pharma's (FLKS) CEO Bill McVicar on Q3 2017 Results - Earnings Call Tran.. 
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 16,4 $
Spread / Average Target 281%
EPS Revisions
Managers
NameTitle
William K. McVicar President, Chief Executive Officer & Director
Christoph H. Westphal Chairman
John McCabe Chief Financial Officer & Treasurer
Thomas C. Wessel Chief Medical Officer
Peter Barton Hutt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC22.63%78
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055